Publication | Closed Access

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial

MedicinePharmacologyClinical TrialsPhase Iii TrialImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyLung CancerPemetrexed Versus PlaceboLume-lung 2